NSE - Delayed Quote INR

Zydus Lifesciences Limited (ZYDUSLIFE.NS)

1,251.20 +5.70 (+0.46%)

As of 10:00:41 AM GMT+5:30. Market Open.

Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

CNW Group 19d ago

ZYDUSLIFE.NS
+0.46%
FYB.DE
Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

PR Newswire 19d ago

ZYDUSLIFE.NS
+0.46%
FYB.DE
Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

CNW Group 27d ago

ZYDUSLIFE.NS
+0.46%
ZYDUSLIFE.BO

ZYDUSLIFE
Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

PR Newswire 27d ago

ZYDUSLIFE.NS
+0.46%
ZYDUSLIFE.BO

ZYDUSLIFE
Zydus Lifesciences Ltd (BOM:532321) (Q1 2027) Earnings Call Highlights: Robust 66. ...

GuruFocus.com 2mo ago

ZYDUSLIFE.NS
+0.46%
Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027

Business Wire 4mo ago

ZYDUSLIFE.NS
+0.46%
ASRT
Zydus Lifesciences Ltd (BOM:532321) Q4 2026 Earnings Call Highlights: Record Growth and ...

GuruFocus.com 5mo ago

ZYDUSLIFE.NS
+0.46%
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

PR Newswire 9mo ago

ZYDUSLIFE.NS
+0.46%
AGEN
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal

Hospital Management 9mo ago

AGEN

ZYDUSLIFE.NS
+0.46%
Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC

PR Newswire 20d ago

ZYDUSLIFE.NS
+0.46%
Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

Pharmaceutical Technology 2mo ago

ZYDUSLIFE.NS
+0.46%
AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer

PR Newswire 7mo ago

ZYDUSLIFE.NS
+0.46%

U.S. markets open in 9h 15m

Zydus Lifesciences Limited (ZYDUSLIFE.NS)

Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

Zydus Lifesciences Ltd (BOM:532321) (Q1 2027) Earnings Call Highlights: Robust 66. ...

Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027

Zydus Lifesciences Ltd (BOM:532321) Q4 2026 Earnings Call Highlights: Record Growth and ...

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal

Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC

Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer